Literature DB >> 2832032

Clinical management of recurrent hepatocellular carcinoma after primary resection.

T Kanematsu1, T Matsumata, K Takenaka, Y Yoshida, H Higashi, K Sugimachi.   

Abstract

Curative resections were performed on 121 patients with primary hepatocellular carcinoma from 1975 to 1986 at Kyushu University Hospital, Japan. Up to August 1987 there was a recurrence in 41, detected between 4 and 86 (mean 20) months after surgery. Intrahepatic recurrences were the most common (82 per cent). There was no statistically significant correlation between size of the primary tumour and interval from surgery to detection of recurrence (r = -0.09). Serial measurement of serum alpha-fetoprotein (AFP) was useful for the detection of recurrences. However, the levels of AFP seem to be a non-specific, unreliable test for such patients since this tumour marker showed different ranges before the primary surgery and at the time of recurrence in 5 of the 41 patients (12 per cent). Postoperative chemotherapy with oral 5-fluorouracil had no apparent preventative effect on the recurrence. A second curative resection was effective in four patients, and three survived for over 2 years; the longest survival time is 9 years after the second procedure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2832032     DOI: 10.1002/bjs.1800750305

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  24 in total

1.  Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma.

Authors:  A Nakayama; H Imamura; Y Matsuyama; H Kitamura; S Miwa; A Kobayashi; S Miyagawa ; S Kawasaki
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

2.  Hepatocellular carcinoma.

Authors:  T Ezaki
Journal:  BMJ       Date:  1992-01-25

3.  Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients-a Retrospective Study.

Authors:  Pin-Gao Yan; Ruo-Yu Wang; Jin Zhang; Wen-Ming Cong; Hui Dong; Hong-Yu Yu; Wan Yee Lau; Meng-Chao Wu; Wei-Ping Zhou
Journal:  J Gastrointest Surg       Date:  2018-01-08       Impact factor: 3.452

4.  Recurrence after resection of alpha-fetoprotein-positive hepatocellular carcinoma.

Authors:  X D Zhou; Z Y Tang; Y Q Yu; B H Yang; J Z Lu; Z Y Lin; Z C Ma; B H Zhang
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Surgical margin and recurrence after resection of hepatocellular carcinoma in patients with cirrhosis. Further evaluation of limited hepatic resection.

Authors:  Y Yoshida; T Kanematsu; T Matsumata; K Takenaka; K Sugimachi
Journal:  Ann Surg       Date:  1989-03       Impact factor: 12.969

6.  Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma.

Authors:  C M Lo; E C Lai; C L Liu; S T Fan; J Wong
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

7.  The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas.

Authors:  T Nonami; K Isshiki; H Katoh; W Kishimoto; A Harada; A Nakao; H Takagi
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

8.  Different DNA changes in primary and recurrent hepatocellular carcinoma.

Authors:  S F Ding; R P Jalleh; C B Wood; L Bowles; J D Delhanty; J Dooley; N A Habib
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

9.  Operative results in 143 patients with hepatocellular carcinoma.

Authors:  T Segawa; R Tsuchiya; J Furui; K Izawa; T Tsunoda; T Kanematsu
Journal:  World J Surg       Date:  1993 Sep-Oct       Impact factor: 3.352

10.  Repeat operation for nodular recurrent hepatocellular carcinoma within the cirrhotic liver remnant: a comparison with transcatheter arterial chemoembolization.

Authors:  K S Jeng; F S Yang; H J Chiang; I Ohta
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.